Crossmark

Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Crossref DOI link: https://doi.org/10.1186/s40425-019-0689-7

Published Online: 2019-08-08

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Florou, Vaia http://orcid.org/0000-0001-5558-753X
Rosenberg, Andrew E.

Wieder, Eric

Komanduri, Krishna V.

Kolonias, Despina

Uduman, Mohamed

Castle, John C.

Buell, Jennifer S.

Trent, Jonathan C.

Wilky, Breelyn A.
License Information

Text and Data Mining valid from 2019-08-08
More Information

Article History

Received: 2 April 2019

Accepted: 23 July 2019

First Online: 8 August 2019

Change Date: 6 November 2019

Change Type: Correction

Change Details: Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells”.

Ethics approval and consent to participate

: Approval for this retrospective study was obtained from the University of Miami IRB.

: Individual patient consent was not applicable as no information in this article are identifiable.

: MU, JCC, JSB are employees of Agenus. BAW is receiving research funding from Agenus. Remaining authors declare no competing interests.